Network News
Heidelberg, March 13, 2026 – Thursday, March 12, 2026, the boundaries of what is scientifically feasible and technically possible in cancer research were pushed further into the future: The approximately 130 participants at the GENESIS 26 – The LIFE SCIENCE TECH DAY forum hosted by InnovationLab GmbH did not merely content themselves with the scientific […]
read more
Prof. Gudrun Rappold receives medal of honor from the German Society for Human Genetics
Prof. Dr. Gudrun Rappold, senior professor at Heidelberg University’s Medical Faculty, has been awarded the Medal of Honor by the German Society for Human Genetics. The Medal of Honor is the highest award given by the professional association and recognizes outstanding scientific achievements in human genetics as well as special contributions to the advancement of […]
read more
Universität Heidelberg Defends its Status as a University of Excellence
Rector Frauke Melchior: “A fantastic joint effort led to success” Heidelberg University has been successful in all previous rounds of the excellence competition and, in the current funding round, has convincingly defended its status as a University of Excellence. That announcement came today (Wednesday, 11 March 2026) from the German Science and Humanities Council and […]
read more
FGK Clinical Research establishes operational presence in the Netherlands to bolster European clinical trial landscape
[Munich, 10/03/2026] — FGK Clinical Research GmbH, a leading full-service Contract Research Organization (CRO) headquartered in Germany, is thrilled to announce the further expansion of its operative team in the Netherlands. This strategic regional expansion strengthens FGK’s European presence and commitment to high-quality clinical research services. The local Dutch team will support clinical studies in the […]
read more
Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement and the Participation of Soleus Capital
Ladenburg, Germany, 9 March 2026 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), announced on 7 March an additional amendment to its existing royalty purchase agreement with HealthCare Royalty (HCRx) and the participation of Soleus Capital Management, L.P. (Soleus Capital), a US-based life sciences investment firm, on behalf […]
read more
Still among the world’s best: Heidelberg University Hospital to remain one of the top hospitals in 2026
According to the US magazine Newsweek, Heidelberg University Hospital (UKHD) remains one of the best hospitals in the world. For its “World’s Best Hospitals 2025” ranking, Newsweek teamed up with the data platform Statista to examine 2,500 hospitals in 32 countries. The UKHD came in 12th place worldwide. In Germany, the UKHD ranks second—only Berlin’s […]
read more
2025 business results – Roche in Germany reports positive results: Roche defies the trend and invests over 700 million euros in Germany
While large parts of the German economy are stagnating, Roche is sending an encouraging signal for Germany as a business location: in fiscal year 2025, the company invested over €700 million in its German sites and increased its sales by 4.7 percent to €8.9 billion. This growth is based on targeted investments in medical progress […]
read more
VERAXA Biotech Shareholders Approve Merger and Issuance of New Shares to Voyager Acquisition Corp.
VERAXA’s shareholders approved the merger between VERAXA and Veraxa Biotech Holding AG and the issuance of new shares of the combined company at the Extraordinary General Meeting. Both resolutions are prerequisites for the closing of the proposed business combination among VERAXA, Veraxa Biotech Holding AG and Voyager Acquisition Corp. ZURICH, SWITZERLAND – March 2, 2026 […]
read more
Ikarovec to advance pipeline with exclusive worldwide option to VectorBuilder’s Intravitreal Capsid Technology
Novel capsid technology to enable convenient delivery in the doctor’s office of IKAR-003 for intermediate AMD, designed to prevent progression to sight-threatening disease NORWICH, UK & CHICAGO, US, January 6 2026 – Ikarovec Ltd, which is developing dual-pathway gene therapies for vision-threatening retinal diseases, and VectorBuilder, a global leader in gene delivery technologies, have entered into an exclusive […]
read more
